Literature DB >> 31171645

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Thijs W H Flinsenberg1, Charnelle C Tromedjo2, Nan Hu3, Ye Liu3, Yin Guo3, Kevin Y T Thia2, Tahereh Noori2, Xiaomin Song3, Han X Aw Yeang2,4, Daniela G Tantalo2, Sasanka Handunnetti5,6, John F Seymour5,6, Andrew W Roberts5,6, David Ritchie5,6,7, Rachel Koldej5,7, Paul J Neeson2,4, Lai Wang3, Joseph A Trapani2,4, Constantine S Tam8,6, Ilia Voskoboinik1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31171645      PMCID： PMC7012496          DOI： 10.3324/haematol.2019.220590

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells.

Authors:  Kerstin Juelke; Monica Killig; Merlin Luetke-Eversloh; Eliana Parente; Joachim Gruen; Barbara Morandi; Guido Ferlazzo; Andreas Thiel; Isabela Schmitt-Knosalla; Chiara Romagnani
Journal:  Blood       Date:  2010-05-26       Impact factor: 22.113

2.  Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Authors:  Holbrook E Kohrt; Idit Sagiv-Barfi; Sarwish Rafiq; Sarah E M Herman; Jonathon P Butchar; Carolyn Cheney; Xiaoli Zhang; Joseph J Buggy; Natarajan Muthusamy; Ronald Levy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

3.  Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.

Authors:  Heinrich Schlums; Frank Cichocki; Bianca Tesi; Jakob Theorell; Vivien Beziat; Tim D Holmes; Hongya Han; Samuel C C Chiang; Bree Foley; Kristin Mattsson; Stella Larsson; Marie Schaffer; Karl-Johan Malmberg; Hans-Gustaf Ljunggren; Jeffrey S Miller; Yenan T Bryceson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

4.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

5.  Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Authors:  Constantine S Tam; Mary Ann Anderson; Christiane Pott; Rishu Agarwal; Sasanka Handunnetti; Rodney J Hicks; Kate Burbury; Gillian Turner; Juliana Di Iulio; Mathias Bressel; David Westerman; Stephen Lade; Martin Dreyling; Sarah-Jane Dawson; Mark A Dawson; John F Seymour; Andrew W Roberts
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

6.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 7.  New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?

Authors:  Simon Rule; Robert W Chen
Journal:  Expert Rev Hematol       Date:  2018-08-02       Impact factor: 2.929

8.  Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.

Authors:  Dianne Khurana; Laura N Arneson; Renee A Schoon; Christopher J Dick; Paul J Leibson
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 9.  The Broad Spectrum of Human Natural Killer Cell Diversity.

Authors:  Aharon G Freud; Bethany L Mundy-Bosse; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

Review 10.  Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors:  Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
View more
  14 in total

Review 1.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

Review 2.  Zanubrutinib: First Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2020-01       Impact factor: 9.546

3.  Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

Authors:  Jacob D Soumerai; Anthony R Mato; Ahmet Dogan; Venkatraman E Seshan; Erel Joffe; Kelsey Flaherty; Jason Carter; Ephraim Hochberg; Jeffrey A Barnes; Audrey M Hamilton; Jeremy S Abramson; Connie L Batlevi; Matthew J Matasar; Ariela Noy; Colette N Owens; M Lia Palomba; Anita Kumar; Tak Takvorian; Ai Ni; Morgan Choma; Chaya Friedman; Puja Chadha; Elizabeth Simkins; Jade Ruiters; Sidney Sechio; Daneal Portman; Lauren Ramos; Natascha Nolet; Neena Mahajan; Rosalba Martignetti; Joanna Mi; Krista Scorsune; Julia Lynch; Brianne McGree; Stephanie Hughes; Clare Grieve; Lindsey E Roeker; Meghan Thompson; P Connor Johnson; Mikhail Roshal; Jane Huang; Juliana Biondo; Qun Wu; Allison Jacob; Omar Abdel-Wahab; Andrew D Zelenetz
Journal:  Lancet Haematol       Date:  2021-12       Impact factor: 30.153

4.  Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo.

Authors:  Xiupeng Ye; Meijing Liu; Cuicui Lv; Yeqiong Li; Lan Chen; Jin Zhang; Juan Mu; Qi Deng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 5.  Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.

Authors:  Joanna M Rhodes; Anthony R Mato
Journal:  Drug Des Devel Ther       Date:  2021-03-02       Impact factor: 4.162

Review 6.  Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.

Authors:  Hussein A Abbas; William G Wierda
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 7.  Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.

Authors:  Xuetong Chu; Yizhi Bu; Xiaoping Yang
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

8.  Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.

Authors:  Chia Sharpe; Joanne E Davis; Kylie Mason; Constantine S Tam; Rachel M Koldej; David S Ritchie
Journal:  J Transl Med       Date:  2021-11-22       Impact factor: 5.531

Review 9.  BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Authors:  Marzia Palma; Tom A Mulder; Anders Österborg
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 10.  Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.

Authors:  Tingyu Wen; Jinsong Wang; Yuankai Shi; Haili Qian; Peng Liu
Journal:  Leukemia       Date:  2020-10-29       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.